WithdrawnPhase 3

Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients

Stopped: We failed to recruit patients

South Korea0Started 2014-01

Plain-language summary

The aim of this study is to evaluate whether long-term rifaximin administration reduces spontaneous bacterial peritonitis recurrence rate in cirrhotic patients.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Decompensated cirrhotic patients with
✕. Active gastrointestinal bleeding
✕. Hepatic encephalopathy \> grade 2
✕. Patients who have clinical, biochemical or radiological data suggesting hepatocellular carcinoma

What they're measuring

The recurrence rate of spontaneous bacterial peritonitis

Timeframe: every 4 weeks, up to 24 weeks

Trial details

NCT IDNCT02011841

SponsorSeoul National University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-12

View on ClinicalTrials.gov More Spontaneous Bacterial Peritonitis trials